The abstract is read at the publisher; the summary is JClub's.
Prophylactic SynFlow 3.0 micro-axial flow pump during non-emergent high-risk PCI in patients with LVEF ≤35% is non-inferior to VA-ECMO for 30-day major adverse events (7.34% vs 11.5%).
- Why it matters: It is unclear whether prophylactic mechanical circulatory support with a micro-axial flow pump or VA-ECMO improves outcomes during high-risk PCI in patients with severely reduced left ventricular function.
- What they did: In a prospective multicentre randomized open-label non-inferiority trial, patients with complex coronary disease and LVEF ≤35% received either SynFlow 3.0 or VA-ECMO during high-risk PCI, with 30-day major adverse events as the primary endpoint.
- The result: SynFlow 3.0 reduced post-procedural hospital stay (4.1 vs 5.2 days, P=.047) and device-related adverse events (3.7% vs 11.5%, P=.041), while anaemia was more frequent with VA-ECMO (20.4% vs 9.2%, P=.023).
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.